Researchers at Columbia University have successfully created the world’s first computer chip powered by an isolated chemical biological process. Natural systems emit enormous amounts of energy that is often underutilized. This new bio-chip represents a high-tech version of “working with nature” and is producing promising results in the laboratory.
Posted in biotech/medical, life extension
The SENS Research Foundation is taking a repair based approach to aging to prevent the diseases and ill health of old age. Visit http://www.sens.org/ to learn more about their work.
Globally, antimicrobial resistance or AMR is becoming a core political, social and economic problem. The implications could never be more real than in Asia where, if no immediate action is taken, by 2050 about five million people are projected to die every year of conditions linked to bacterial infections resistant to antibiotics. This figure will be more than estimated cancer fatalities.
Katinka De Balogh says governments, individuals and health care professionals must all act to curb misuse before antibiotic-resistant bacteria creates a public health calamity.
The sense of touch is often taken for granted. For someone without a limb or hand, losing that sense of touch can be devastating. While highly sophisticated prostheses with complex moving fingers and joints are available to mimic almost every hand motion, they remain frustratingly difficult and unnatural for the user. This is largely because they lack the tactile experience that guides every movement. This void in sensation results in limited use or abandonment of these very expensive artificial devices. So why not make a prosthesis that can actually feel its environment?
That is exactly what an interdisciplinary team of scientists from Florida Atlantic University and the University of Utah School of Medicine aims to do. They are developing a first-of-its-kind bioengineered robotic hand that will grow and adapt to its environment. This living robot will have its own peripheral nervous system directly linking robotic sensors and actuators. FAUs College of Engineering and Computer Science is leading the multidisciplinary team that has received a four-year, $1.3 million grant from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health for a project titled Virtual Neuroprosthesis: Restoring Autonomy to People Suffering from Neurotrauma.
Interesting article about the longevity work of my friend James Clement in The New York Times: https://nyti.ms/2hw8W32 #transhumanism
James Clement has scoured the globe for supercentenarians, aged 110 and older, willing to contribute their genomes to a rare scientific cache.
It’s all a question of money. We should come up with enough money for funding this so that we can clone a perfect genetic match of every organ in the body by 2025. It will solve the organ shortage issue, and nip the illegal black market organ industry in the bud.
The FDA said it is looking into “regenerative medicine.”
Today, we take a look at three key emerging technologies that might add extra healthy years to your life by addressing the aging processes directly to prevent or delay age-related diseases.
Senolytics – Removing aged dysfunctional cells to promote tissue regeneration
As we age, increasing amounts of our cells enter into a state known as senescence. Normally, these cells destroy themselves by a self-destruct process known as apoptosis and are disposed of by the immune system. Unfortunately, as we age, increasing numbers of these cells evade apoptosis and linger in the body.
T he world’s first human head transplant has been carried out on a corpse in China in an 18-hour operation that showed it was possible to successfully reconnect the spine, nerves and blood vessels.
At a press conference in Vienna on Friday morning, Italian Professor Sergio Canavero, director of the Turin Advanced Neuromodulation Group, announced that a team at Harbin Medical University had “realised the first human head transplant” and said an operation on a live human will take place “imminently”.
The operation was carried out by a team led by Dr Xiaoping Ren, who last year successfully grafted a head onto the body of a monkey.
On Wednesday—for only the second time—the Food and Drug Administration approved a cutting-edge therapy that genetically modifies a patient’s blood cells in order to attack cancer. This time the therapy, known as CAR T-cell therapy, is designed to treat aggressive non-Hodgkin lymphoma.
In August, the FDA approved the first CAR T-cell therapy, for a drug called Kymriah designed for children and young adults whose leukemia doesn’t respond to standard treatments. The FDA’s approval of Yescarta, manufactured by Kite Pharma, comes just a few months after its first approval—an indication of just how quickly the field of immunotherapy is moving. Several other companies also have CAR-T therapies in the works.
